REAL‐LIFE EXPERIENCE WITH RITUXIMAB‐DOSE‐ADJUSTED EPOCH (R‐da‐EPOCH) IN PRIMARY MEDIASTINAL LARGE B‐CELL LYMPHOMA (PMLBCL): A MULTINATIONAL ANALYSIS OF 274 PATIENTS.

REAL-LIFE EXPERIENCE WITH RITUXIMAB-DOSE-ADJUSTED EPOCH (R-da-EPOCH) IN PRIMARY MEDIASTINAL LARGE B-CELL LYMPHOMA (PMLBCL): A MULTINATIONAL ANALYSIS OF 274 PATIENTS B Background: b Real-life studies of moderate size have shown satisfactory but less impressive results compared with the original R-da-EPOCH publication for PMLBCL. B Conclusions/Discussion: b In the largest series reported so far for R-da-EPOCH in PMLBCL, FFP appeared somewhat but not impressively better than the expected with R-CHOP, but this was achieved with the safe omission of RT was in >85% of responders. [Extracted from the article]